Shares of Moderna Inc. rallied toward a 5th consecutive summation Tuesday, aft Morgan Stanley expert Matthew Harrison added astir $150 to his terms people connected an accrued outlook for the biotechnology company’s COVID-19 vaccine sales.
Meanwhile, helium downgraded respective different biopharma stocks, including those of COVID-19 vaccine shaper Johnson & Johnson JNJ, -1.59%, citing valuation concerns, of Merck & Co. Inc. MRK, -1.63% fixed deficiency of imaginable upside catalysts and of Amgen Inc. AMGN, -2.22% connected valuation. All 3 of those stocks are Dow Jones Industrial Average DJIA, -0.76% components.
Moderna’s banal MRNA, +4.73% changeable up 4.8% successful day trading. It has present rallied 17.8% implicit the past 5 days, but remains 9.9% beneath its Aug. 9 grounds adjacent of $484.47. The banal is headed for its longest triumph streak since the five-day agelong of gains ended May 28.
Harrison raised his terms people connected Moderna’s banal by astir 77%, to $337 from $190.
He besides raised is COVID-19 income estimation for 2021 to $20.25 cardinal from $19.13 cardinal and his outlook for 2022 income to $30.38 cardinal from $13.50 billion. The caller estimates relationship for greater vaccine usage, including a 3rd booster changeable arsenic portion of the superior series.
“We proceed to spot COVID-19 revenues declining implicit time, but we bash not spot that starting to hap until 2023/2024 versus our anterior estimation of 2022,” Harrison wrote successful a enactment to clients. “We person besides added successful the imaginable for a operation COVID/respiratory vaccine.”
He reiterated his adjacent value standing connected the stock, arsenic his terms people is astir 23% beneath existent levels. “While we judge determination is semipermanent upside for Moderna, we judge the important valuation summation associated with the occurrence of the COVID-19 vaccine limits the near-term upside,” Harrison wrote.
The banal has rocketed 597.5% implicit the past 12 months, portion shares of J&J person gained 15.8% and of Pfizer Inc. PFE, -0.15%, which besides has a COVID-19 vaccine on with its spouse BioNTech SE BNTX, +3.68%, person precocious 35.4%. Over the aforesaid time, the SPDR S&P Pharmaceuticals exchange-traded money XPH, -0.72% has tacked connected 12.4% and the S&P 500 scale SPX, -0.34% has rallied 32.1%.
Separately, Harrison downgraded J&J to adjacent value from overweight, portion keeping his banal terms people astatine $187.
“Management is delivering coagulated fiscal results, but banal has tally up successful caller months and we spot constricted quality travel successful the midterm to thrust shares higher,” Harrison wrote.
The stock, which shed 1.7% successful day trading Friday, has gained 4.4% implicit the past 3 months, and reached a grounds closing precocious of $179.47 arsenic precocious arsenic Aug. 17. In comparison, the pharmaceutical ETF has declined 5.5% implicit the past 3 months.
Harrison said the adjacent cardinal lawsuit for investors to ticker is Pharma Day connected Nov. 18, astatine which clip J&J is expected to stock pipeline merchandise details and item cause candidates with important marketplace potential.
Merck was besides downgraded to adjacent value from overweight, and had its terms people chopped to $85 from $90. He said portion absorption is apt to support driving upside for it cardinal crab attraction Keytruda, helium doesn’t judge investors volition wage for that upside fixed concerns implicit deficiency of loss-of-exclusivity (LOE) diversification.
“Investors are not convinced that the existent pipeline assets, including HIV cause islatravir and aboriginal oncology assets, are capable to offset the Keytruda cliff astatine the extremity of the decennary fixed pivotal information volition not work retired until 2024-2025,” Harrison wrote.
The banal fell 1.8% successful day trading.
Amgen’s banal shed 2.6%, putting them connected way for the lowest adjacent since late-November.
Harrison besides chopped his standing to adjacent value from overweight, portion besides slashing his terms people to $251 from $280.
“Our caller thesis is based connected a much balanced risk/reward arsenic investors absorption connected the mid-decade LOEs for Evenity, XGENA and Prolia, offset by continued pipeline progress,” Harrison wrote.
Among different ratings moves, Harrison besides downgraded argenx SE ARGX, -2.88% ARGX, -2.19% to adjacent value from overweight, and Genmab A/S GMAB, -3.43% GMAB, -4.39% and Vertex Pharmaceuticals Inc. VRTX, -2.95% to underweight from adjacent weight.
Shares of argenx dropped 2.9% successful day trading, Genmab gave up 3.7% and Vertex declined 2.9%.
English (US) ·